Actively Recruiting
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Led by Peking Union Medical College Hospital · Updated on 2024-07-05
90
Participants Needed
1
Research Sites
228 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
CONDITIONS
Official Title
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed or suspected breast, brain, or prostate cancer
- Undergoing 68Ga-RM26-RGD and 18F-FDG (or 68Ga-RM26 or 68Ga-RGD) PET/CT scans within 2 weeks
- Signed written informed consent
You will not qualify if you...
- Pregnancy
- Breastfeeding
- Any medical condition that may significantly interfere with study compliance, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
Z
Zhaohui Zhu, MD,PHD
CONTACT
Z
Zhaohui Zhu, MD,PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here